HIV-positive individuals with a viral load below 200 while on antiretroviral therapy did not transmit HIV to steady sex partners during more than one year of condomless sex.
Recognizing Collective Efforts, 85 Leaders From 19 Nations Receive 2016 Omololu Falobi HIV Prevention Advocacy Award
On 10th anniversary of Omololu Falobi's passing, the HIV award in his name celebrates the entire movement by acknowledging all advocates who were nominated, each of whom represents thousands of others.
"Let's not throw condoms out with the bath water!" Shaun Barcavage, N.P., writes. "They still have a role to play in protecting the sexual health of gay men -- since they can protect against STIs in addition to HIV."
Taking antiretroviral therapy did not raise the likelihood of sex without condoms in a cross-sectional study of 3178 men and women in the United Kingdom.
Antiretroviral treatment as prevention (TasP) in Denmark could nearly eliminate the HIV epidemic among men who have sex with men (MSM), according to predictions of a Bayesian back-calculation model.
Negligible Risk: Updated Results From Two Studies Continue to Show That Antiretroviral Treatment and an Undetectable Viral Load Is a Highly Effective HIV Prevention Strategy
Interim analyses from two important studies clearly demonstrated that ART and an undetectable viral load is a highly effective HIV prevention strategy for heterosexual and gay male serodiscordant couples.
From 2005 to 2014, condomless anal sex rose among U.S. men who have sex with men (MSM) with or without HIV infection. Neither serosorting nor use of antiretroviral therapy (ART) explained falling condom use in this study of almost 36,000 MSM.
Consistent Use of Dapivirine Vaginal Ring Could Offer More Than 75% HIV Protection, New Data Suggests
Seventy-five percent: That's how much HIV protection women might be able to expect from a flexible silicone ring loaded with the antiretroviral medicine dapivirine when they put it in their vaginas and leave it there.
Rilpivirine (Edurant) remained detectable in plasma and female genital tract fluids for 18 months or more after a single injection of a long-acting non-nucleoside for HIV pre-exposure prophylaxis (PrEP).
Twice-daily oral maraviroc (Selzentry, Celsentri) failed to prevent SIV infection in infant macaques orally exposed to the virus, but the findings do not rule out potential use in human infants.